Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

IGABT effective at controlling return and spread of cervical cancer

Delivering radiotherapy directly to cancer of the cervix using 3-D imaging techniques is effective at controlling the return and spread of the disease and, in most cases, avoids the need for hysterectomies, according to research presented at the World Congress of Brachytherapy today.

11 May 2012

$Onconova advances rigosertib into new Phase II study for refractory MDS$

Onconova advances rigosertib into new Phase II study for refractory MDS

Onconova Therapeutics, Inc., announced today the advancement of the oral formulation of rigosertib, an anti-cancer agent with demonstrated activity in solid tumors and hematologic malignancies, into a new Phase II study. The intravenous (IV) formulation of rigosertib is currently in a pivotal Phase III trial for refractory myelodysplastic syndromes (MDS) in the U.S. and EU.

11 May 2012

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

"Bacteria, viruses and parasites cause around two million cases of cancer in the world each year, experts believe," the Press Association/Guardian reports. According to the news service, "Scientists carried out a statistical analysis of cancer incidence to calculate that around 16 percent of all cancers diagnosed in 2008 were infection-related," and "the proportion of cancers linked to infection was three times higher in developing countries than in developed ones."

10 May 2012

Lenalidomide improves overall survival for patients with multiple myeloma

Data from the first large U.S. study assessing the effectiveness of long-term "maintenance" therapy with lenalidomide for patients with multiple myeloma show that the drug significantly improves the time to progression and overall survival for patients with this often-deadly hematologic cancer.

10 May 2012

LWW wins 21 awards in 15 categories from ASHPE

Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, is pleased to announce that it has won 21 awards in 15 categories, which is a record number of wins in a single year for LWW overall. ASHPE's 12th annual awards competition recognizes member articles and publications for editorial, design, print, and online award categories.

10 May 2012

Resverlogix completes RVX-208 Phase 2b trial on CVD

Resverlogix Corp. is pleased to announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess lipid trends and safety of RVX-208, has been completed on schedule.

10 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Shire, Cosmo and Giuliani International file suit against Watson over generic Lialda

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda.

10 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Poor women and African Americans with ovarian cancer less likely to receive care

Poor women and African Americans with ovarian cancer are less likely to receive the highest standards of care, leading to worse outcomes than among white and affluent patients, according to a study of 50,000 women presented by UC Irvine's Dr. Robert Bristow at the Society of Gynecologic Oncology's annual meeting March 27.

9 May 2012

Study offers new insight on known link between exposure to violence and sexual risk-taking

Women who have experienced multiple forms of violence, from witnessing neighborhood crimes to being abused themselves, are more likely to engage in risky sexual behavior, according to a new report in the Psychology of Violence.

9 May 2012

IBN develops biochip for investigating the effect of drugs on cancer stem cells

Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs). Published recently in Nano Today, this new technology could boost the development of more effective cancer drugs.

9 May 2012

Teva first quarter net revenues increase 25% to $5.1 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2012.

9 May 2012

Women & Infants Hospital to receive Health Care Innovation award

Health and Human Services Secretary Kathleen Sebelius today announced that Women & Infants Hospital of Rhode Island is among the first batch of organizations selected for Health Care Innovation awards. Made possible by the health care law - the Affordable Care Act - the awards will support 26 innovative projects nationwide that will save money, deliver high quality medical care, and enhance the health care workforce. The preliminary awardees announced today expect to reduce health spending by $254 million over the next three years.

9 May 2012

Basser Research Center to focus on treatment and prevention of inherited cancers

A $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray will establish a center focused on the treatment and prevention of cancers associated with hereditary BRCA mutations.

9 May 2012

More teenagers and young adults diagnosed with skin cancer

With summer just around the corner, pediatricians at Johns Hopkins Children's Center are sounding the alarm on a disturbing trend: A growing number of teenagers and young adults diagnosed with skin cancer.

8 May 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

From Santen Pharmaceutical Co., Ltd. 8 May 2012

Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

8 May 2012

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two patients have been enrolled into REALISTIC, a Phase 1/2 study being sponsored by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

8 May 2012

Amakem presents key preclinical data on AMA0076 at ARVO meeting

Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.

8 May 2012